GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-  
A8516 Rizatriptan BenzoateSummary: 5-HT Receptor agonist -  
B1333 Clonidine HClSummary: α2-adrenergic receptor agonist -  
B7096 Tocrifluor T1117Summary: Fluorescent form of AM 251, CB1 receptor antagonist -  
B6794 HEMADOSummary: adenosine A3 receptor agonist -  
A8514 RisperidoneSummary: SR-2A inhibitor -  
B1332 CarvedilolSummary: Potent β-adrenoceptor and α1-adrenoceptor antagonist -  
B6705 PD 81723Summary: Allosteric potentiator at the adenosine A1 receptor -  
B7073 JTE 907Summary: cannabinoid CB2 receptor inverse agonist -  
A8421 Duloxetine HClSummary: 5-HT receptor inhibitor -  
B1331 Adrenalone HClSummary: Adrenergic receptor agonist 
